IN8bio to Present at July Investor and Scientific Conferences

Rhea-AI Summary

IN8bio (Nasdaq: INAB) has announced its participation in key conferences this July, focusing on its innovative gamma-delta T cell therapies. The company will present at the Oppenheimer Summit on July 20, with CFO Patrick McCall and CMO Dr. Trishna Goswami available for 1x1 partnering. Additionally, at the 3rd Annual Gamma-Delta T Cell Therapies Summit in Boston (July 26-28), CSO Lawrence Lamb will lead discussions and presentations on maximizing therapeutic outcomes. Lastly, CEO William Ho will deliver a keynote at the GEN Cell & Gene Therapy Summit on July 27.

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced July conference presentations:

• Oppenheimer Summit for Emerging Biotechnology (Montauk), July 20
  • Patrick McCall, CFO, and Dr. Trishna Goswami, CMO, open scheduling for 1x1 partnering

• 3^rd Annual Gamma-Delta T Cell Therapies Summit (Boston), July 26 – 28
  • Lawrence Lamb, Ph.D., CSO, Panel for Industry Leaders’ Fireside Chat
  • July 27, 8:45 a.m. EDT
    
    
  • Lawrence Lamb, Ph.D., CSO, Presenting, “Learning from Patient Selection, Biomarker Studies, and Indications to Maximize Therapeutic Outcomes”
    
  • July 28, 2 p.m. EDT

• Genetic Engineering News (GEN) Cell & Gene Therapy (CGT) Summit (Virtual), July 27
  • William Ho, CEO, Keynote on, “Challenges and Future of Allogeneic Cell Therapies”
  • July 27, 11 a.m. EDT
    

About IN8bio
IN8bio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. IN8bio’s DeltEx platform employs allogeneic, autologous and genetically modified approaches to develop cell therapies, designed to effectively identify and eradicate tumor cells.

IN8bio is currently conducting two investigator-initiated Phase 1 clinical trials for its lead gamma-delta T cell product candidates: INB-200 for the treatment of newly diagnosed glioblastoma and INB-100 for the treatment of patients with leukemia undergoing hematopoietic stem cell transplantation. IN8bio also has a broad portfolio of preclinical programs focused on addressing other solid tumor types. For more information about IN8bio and its programs, please visit www.IN8bio.com.

Contacts
IN8bio, Inc.
Patrick McCall
+1 646.600.6438
pfmccall@in8bio.com

Investors:
Solebury Trout
David Buck
+1 646.378.2927
dbuck@soleburytrout.com

Media:
Burns McClellan, Inc.
Katie Larch / Robert Flamm, Ph.D.
Media.Relations@burnsmc.com

FAQ

What events is IN8bio participating in during July 2022?

IN8bio is participating in the Oppenheimer Summit on July 20, the 3rd Annual Gamma-Delta T Cell Therapies Summit from July 26-28, and the GEN Cell & Gene Therapy Summit on July 27.

Who from IN8bio will present at the Gamma-Delta T Cell Therapies Summit?

CSO Lawrence Lamb will participate in the Industry Leaders’ Fireside Chat and present on patient selection and biomarker studies at the Gamma-Delta T Cell Therapies Summit.

What topic will William Ho discuss at the GEN Summit?

William Ho, CEO of IN8bio, will deliver a keynote address on the challenges and future of allogeneic cell therapies at the GEN Summit on July 27.

What is the focus of IN8bio's gamma-delta T cell therapies?

IN8bio focuses on developing gamma-delta T cell therapies for solid and liquid tumors using its DeltEx platform.

What clinical trials is IN8bio currently conducting?

IN8bio is conducting Phase 1 clinical trials for INB-200 for glioblastoma and INB-100 for leukemia patients undergoing stem cell transplantation.